{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:01:20Z","timestamp":1777287680968,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"9759","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/s0140-6736(10)62175-7","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T04:17:55Z","timestamp":1292905075000},"page":"42-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":911,"title":["Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial"],"prefix":"10.1016","volume":"377","clinical-trial-number":[{"clinical-trial-number":"nct00006721","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00140582","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00227695","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00770224","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00877214","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gilles","family":"Salles","sequence":"first","affiliation":[]},{"given":"John Francis","family":"Seymour","sequence":"additional","affiliation":[]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[]},{"given":"R\u00e9da","family":"Bouabdallah","sequence":"additional","affiliation":[]},{"given":"John Vincent","family":"Catalano","sequence":"additional","affiliation":[]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[]},{"given":"Lars Moller","family":"Pedersen","sequence":"additional","affiliation":[]},{"given":"Alain","family":"Delmer","sequence":"additional","affiliation":[]},{"given":"David","family":"Simpson","sequence":"additional","affiliation":[]},{"given":"Sirpa","family":"Leppa","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Soubeyran","sequence":"additional","affiliation":[]},{"given":"Anton","family":"Hagenbeek","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[]},{"given":"Tanin","family":"Intragumtornchai","sequence":"additional","affiliation":[]},{"given":"Christophe","family":"Ferm\u00e9","sequence":"additional","affiliation":[]},{"given":"Maria Gomes","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"Catherine","family":"Sebban","sequence":"additional","affiliation":[]},{"given":"Andrew","family":"Lister","sequence":"additional","affiliation":[]},{"given":"Jane A","family":"Estell","sequence":"additional","affiliation":[]},{"given":"Gustavo","family":"Milone","sequence":"additional","affiliation":[]},{"given":"Anne","family":"Sonet","sequence":"additional","affiliation":[]},{"given":"Myriam","family":"Mendila","sequence":"additional","affiliation":[]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(10)62175-7_bib1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","article-title":"Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century","volume":"168","author":"Pulte","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/S0140-6736(10)62175-7_bib3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib6","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib7","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib8","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib9","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib10","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib11","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib12","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib14","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","article-title":"Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders","volume":"23","author":"Gordan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib15","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood.V110.11.3420.3420","article-title":"Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab extended schedule or re-treatment trial (RESORT)","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib17","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib18","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V112.11.2599.2599","article-title":"Rituximab in combination with CHOP in patients with follicular lymphoma: Analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58 months","volume":"112","author":"Buske","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(10)62175-7_bib22","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib23","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib24","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u226avaccinal effect\u226b of rituximab","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","article-title":"Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response","volume":"116","author":"Ab\u00e8s","year":"2010","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1084\/jem.20061292","article-title":"Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis","volume":"203","author":"Roulland","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/S0140-6736(10)62175-7_bib27","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2008-08-174839","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone","volume":"113","author":"Carlotti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib28","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood-2007-11-124560","article-title":"S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells","volume":"112","author":"Ruminy","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62175-7_bib29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(10)62175-7_bib31","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-A study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"28","author":"Bachy","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62175-7_bib33","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673610621757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673610621757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T23:59:47Z","timestamp":1758844787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673610621757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":32,"journal-issue":{"issue":"9759","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0140673610621757"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(10)62175-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.9990958.10728055","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(10)62175-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(10)62272-6","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}